Pharsight

Eskata is owned by Aclaris.

Eskata contains Hydrogen Peroxide.

Eskata has a total of 6 drug patents out of which 1 drug patent has expired.

Expired drug patents of Eskata are:

Eskata was authorised for market use on 14 December, 2017.

Eskata is available in solution;topical dosage forms.

Eskata can be used as treatment of seborrheic keratoses that are raised.

The generics of Eskata are possible to be released after 04 July, 2035.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381427	ACLARIS	Seborrheic keratosis treatment	Jun, 2022 (8 months ago)
US10098910	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (12 years from now)
US9980983	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (12 years from now)
US10493103	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (12 years from now)
US10729720	ACLARIS	Peroxide formulations and methods and applicators for using the same	Apr, 2035 (12 years from now)
US9675639	ACLARIS	Peroxide formulations and methods and applicators for using the same	Jul, 2035 (12 years from now)